Filter Results


Study status

(for at least one location)



Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-6 of 6 for Essential thrombocythemia

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. PAC203: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL) (PACIFICA)

    Scottsdale/Phoenix, AZ

  2. A Study to Evaluate 9-ING-41 As a Single Agent or in Combination with Ruxolitinib in Myelofibrosis Patients

    Rochester, MN

  3. A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis

    Jacksonville, FL

  4. A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM)

    Scottsdale/Phoenix, AZ

  5. A Study to Compare the Effectiveness, Safety and Tolerability of P1101 vs. Anagrelide for Essential Thrombocythemia

    Scottsdale/Phoenix, AZ

  6. A Study to Evaluate Exercise for Cancer Patients at Risk of Falling

    Rochester, MN


Mayo Clinic Footer